In the five years since Philadelphia’s first hormone-replacement therapy case went to trial, a jury has awarded punitive damages as high as $75 million, more than 1,000 cases have been tossed out of court and then revived on appeal, and HRT drugmaker Wyeth was bought by Pfizer.

Now, settlement is the name of the game in Philadelphia’s largest pharmaceutical litigation since the 10,000-strong diet drug litigation of the mid-2000s.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]